On November 17, 2025 Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL gene silencing technology to eliminate cancer reported that a podium presentation highlighting INTASYL siRNA Drug Technology will be held at the Advanced Therapies USA 2025 Congress in Philadelphia, PA at the Pennsylvania Convention Center from November 18-19, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Podium Presentation Details are as follows:

Title: INTASYL Synthesized siRNA Drug Technology
Down-regulating Gene Expression
Presenting Author: Melissa Maxwell, M.S.
Date: November 18, 2025
Location: Innovation Showcase (Track 2, Seminar Theatre)
Time: 1:15 PM EDT

"The INTASYL siRNA technology represents a promising approach to enhance cancer treatment." said Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals. "Further the INTASYL compound PH-762 may fulfill a medical need for a non-surgical treatment option for patients with cutaneous carcinomas."

(Press release, Phio Pharmaceuticals, NOV 17, 2025, View Source [SID1234660032])